Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Accounts Payables: 2019-2024

Historic Accounts Payables for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $11.5 million.

  • Nurix Therapeutics' Accounts Payables rose 119.73% to $8.6 million in Q3 2025 from the same period last year, while for Aug 2025 it was $8.6 million, marking a year-over-year increase of 119.73%. This contributed to the annual value of $11.5 million for FY2024, which is 79.38% up from last year.
  • According to the latest figures from FY2024, Nurix Therapeutics' Accounts Payables is $11.5 million, which was up 79.38% from $6.4 million recorded in FY2023.
  • Over the past 5 years, Nurix Therapeutics' Accounts Payables peaked at $11.5 million during FY2024, and registered a low of $3.4 million during FY2020.
  • Over the past 3 years, Nurix Therapeutics' median Accounts Payables value was $6.4 million (recorded in 2023), while the average stood at $7.6 million.
  • Per our database at Business Quant, Nurix Therapeutics' Accounts Payables spiked by 113.52% in 2020 and then decreased by 23.85% in 2022.
  • Nurix Therapeutics' Accounts Payables (Yearly) stood at $3.4 million in 2020, then spiked by 94.90% to $6.7 million in 2021, then dropped by 23.85% to $5.1 million in 2022, then climbed by 26.40% to $6.4 million in 2023, then skyrocketed by 79.38% to $11.5 million in 2024.